Burning mouth Syndrome
ICD-10 K14.6 · ICD-11 DA0F

Burning Mouth Syndrome When First-Line Therapy Has Not Controlled Pain

For patients with burning mouth syndrome in whom initial evidence-based treatments have been tried and failed to deliver sustained oral pain reduction, this protocol defines the next clinical step.

Previous Treatment — Failure Condition

When cognitive behavioural therapy, topical capsaicin oral rinse, topical clonazepam, or low-level (photobiomodulation) laser therapy — the interventions with the strongest evidence at first line — did not achieve a sustained reduction in oral burning pain (VAS/VNS score) in both the short term (up to 3 months) and the longer term (beyond 3 months), escalation to an alternative approach is indicated.

Next-Line Approach

This protocol involves oral agents from two therapeutic categories — an antioxidant compound and anticonvulsant medications, including alpha lipoic acid, gabapentin, and pregabalin — used individually or in specific combinations. The complete options, sequencing, and courses remain in the full protocol.

Treatment Goal

Meaningful reduction in oral burning pain as measured on a validated pain scale (VAS). Evidence supports that the benefit of certain agents at this line increases with sustained use beyond three months.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1177/03331024211036152
The pooled ALA suggested a more than double increase in likelihood of pain improvement (RR 2.44, 95% CI 1.57 to 3.78, p < 0.001) compared to placebo.
A combination of 600 mg ALA and 300 mg gabapentin in a randomised, double-blind clinical trial described a notable pain reduction, with 70% of patients demonstrating a partial or complete improvement in pain intensity compared to 15% in the placebo group.
The combined use of ALA and gabapentin gave a five-fold likelihood (RR 4.67, 95% CI 2.40–9.09) (p < 0.001) of decreased pain intensity while ALA only has four times the likelihood of beneficial effect (RR 3.67, 95% CI 1.78 to 7.54).
Combining vitamins such as vitamin C, PP, E, B6, B2, B1, B12 and folic acid with 800 mg ALA did significantly improve VAS score (MD 1.0, SD 1.83, p = 0.047) and a further reduction in VAS score was noted 2 months after termination of treatment (MD 1.8, SD 3.19, p = 0.047).
A more than three-fold likelihood of positive change relative to placebo were reported with the use of gabapentin in the short-term assessment of 20 BMS patients (RR 3.33, 95% CI 1.58–7.02).
At 4 months of assessment, 150 mg pregabalin showed a significant reduction in VAS scores (MD 4.7, p < 0.001).
A 1-year follow-up showed a sustained effect on pain intensity in 73% of patients.
View source ↗